Share your videos with the world

There is only one choice when it come to nutrition that slows down kidney disease and helps joint problems at the same time - The Hill's Science Diet K/D + Mobility. Learn more here: https://tier1petproducts.com/best-dog-food-for-kidney-disease/ Chronic kidney disease (CKD) is a condition often associated with advanced age. According to recent data 1 out of 10 dogs will develop CKD in his lifetime. It is also common for senior dogs to develop other age-related conditions such as reduced mobility or cognitive dysfunction which can significantly impact the quality of life of both the pet and the pet parent. Nutrition can play a key role in managing these age-related conditions. That is why Hill’s nutritionists and veterinarians developed new Prescription Diet K/D + Mobility for dogs.

Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma. To view the multimedia release go to: http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/

Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II. To view the multimedia release go to: https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/